MAP4K1 and cancer: Interestingly, the genetic ablation or pharmacological inhibition of HPK1 kinase activity in cells and animal models have been shown to improve the immune response to cancers, suggesting that HPK1 could be a druggable target for T-cell-based cancer immunotherapy [10–14].